Monoclonal antibodies to nipah virus and their use

Monoclonal antibodies targeting NiV F or G proteins effectively neutralize and inhibit Henipaviruses, addressing the lack of therapeutic agents for NiV and HeV infections, and enabling treatment and detection of these viruses.

WO2026128512A1PCT designated stage Publication Date: 2026-06-18THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
Filing Date
2025-12-09
Publication Date
2026-06-18

AI Technical Summary

⚠Technical Problem

There is a lack of effective therapeutic agents for treating Henipavirus infections, such as Nipah virus (NiV) and Hendra virus (HeV), which can cause severe illness in humans and animals, and existing antibodies are not potent enough to neutralize these viruses effectively.

⚗Method used

Development of monoclonal antibodies and antigen binding fragments that specifically bind to NiV F or G proteins, exhibiting enhanced neutralization capabilities against NiV and cross-reactivity with HeV, along with nucleic acid molecules, vectors, and pharmaceutical compositions for treatment and detection of Henipavirus infections.

🎯Benefits of technology

The developed antibodies and fragments provide potent neutralization and inhibition of Henipavirus infections, offering therapeutic and diagnostic solutions for NiV and HeV, with potential for in vivo protection and improved treatment outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2025058844_18062026_PF_FP_ABST
    Figure US2025058844_18062026_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed are monoclonal antibodies and antigen binding fragments thereof that specifically bind to Nipah virus (NiV) F or G protein. In several examples, the antibodies and antigen binding fragments are cross-reactive with other Henipavirus F or G proteins, such as Hendra virus (HeV) F or G proteins. Also disclosed is the use of these antibodies and antigen binding fragments for inhibiting a Henipavirus infection, such as a NiV and / or HeV infection. In addition, disclosed are methods for detecting Henipavirus, such as NiV or HeV in a biological sample, using the disclosed antibodies and antigen binding fragments.
Need to check novelty before this filing date? Find Prior Art